$1.75 10.6%
CLDI Stock Price vs. AI Score (Last 150 days)
Data gathered: July 16

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors.


Calidi Biotherapeutics
Price $1.75
Target Price Sign up
Volume 448,930
Market Cap $34M
Year Range $0.15 - $2.49
Dividend Yield 0%
Revenue per Employee $83,678
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '2404M-4M-7.2M0-0.203
Q4 '23170,0005.9M-5.7M-8.2M0-0.480
Q3 '2304M-4.3M-2M0-0.140
Q2 '233.3M3.4M-17,000-13M0-0.432
Q1 '232.8M2.8M-16,000-6.5M0-0.225

Insider Transactions View All

No recorded Insider transactions.

What is the Market Cap of Calidi Biotherapeutics?

The Market Cap of Calidi Biotherapeutics is $34M.

How Many People Work at Calidi Biotherapeutics?

As of our latest update, Calidi Biotherapeutics employed approximately 42 people worldwide. However, it's important to note that Calidi Biotherapeutics' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Calidi Biotherapeutics' revenue per employee?

$83,678. To calculate Calidi Biotherapeutics' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Calidi Biotherapeutics?

Currently, the price of one share of Calidi Biotherapeutics stock is $1.75.

How can I analyze the CLDI stock price chart for investment decisions?

The CLDI stock price chart above provides a comprehensive visual representation of Calidi Biotherapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Calidi Biotherapeutics shares. Our platform offers an up-to-date CLDI stock price chart, along with technical data analysis and alternative data insights.

Does CLDI offer dividends to its shareholders?

As of our latest update, Calidi Biotherapeutics (CLDI) does not offer dividends to its shareholders. Investors interested in Calidi Biotherapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Calidi Biotherapeutics?

Some of the similar stocks of Calidi Biotherapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.